Cellectar Biosciences (CLRB) Insider Trading & Ownership $0.36 0.00 (-0.99%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$0.36 +0.00 (+0.50%) As of 03/27/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Cellectar Biosciences (NASDAQ:CLRB) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage3.70%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$8,400.00Number OfInsiders Selling(Last 12 Months)0 Get CLRB Insider Trade Alerts Want to know when executives and insiders are buying or selling Cellectar Biosciences stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CLRB Insider Buying and Selling by Quarter Remove Ads Cellectar Biosciences Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails1/10/2025Jarrod LongcorCOOBuy30,000$0.28$8,400.00 (Data available from 1/1/2013 forward) CLRB Insider Trading Activity - Frequently Asked Questions Who is on Cellectar Biosciences's Insider Roster? The list of insiders at Cellectar Biosciences includes Jarrod Longcor. Learn more on insiders at CLRB. What percentage of Cellectar Biosciences stock is owned by insiders? 3.70% of Cellectar Biosciences stock is owned by insiders. Learn more on CLRB's insider holdings. Which Cellectar Biosciences insiders have been buying company stock? The following insider purchased CLRB shares in the last 24 months: Jarrod Longcor ($8,400.00). How much insider buying is happening at Cellectar Biosciences? Insiders have purchased a total of 30,000 CLRB shares in the last 24 months for a total of $8,400.00 bought. Cellectar Biosciences Key ExecutivesMr. James V. Caruso (Age 65)President, CEO & Director Compensation: $1.14MMr. Chad J. Kolean CPA (Age 60)VP, CFO & Secretary Compensation: $711.23kMr. Jarrod Longcor (Age 51)Chief Operating Officer Compensation: $854.24k1 recent tradesMr. Darrell Shane Lea (Age 50)Chief Commercial Officer Dr. Andrei Shustov M.D. (Age 52)Senior Vice President of Medical More Insider Trading Tools from MarketBeat Related Companies ANRO Insider Trades SKYE Insider Trades ALGS Insider Trades ADAP Insider Trades ENTX Insider Trades EPIX Insider Trades ALTS Insider Trades ZIVO Insider Trades SCLX Insider Trades UNCY Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles NVIDIA Insiders Sell: This Is What It Means for the Market Top 3 Insider Stock Buys in March—Are They Still Good in April?Grocery Outlet Insider and Institutional Buyers Signal BottomSentinelOne Insider Selling? Why Investors Should Stay Bullish 3 Companies Buying Back Stock—Why It Matters This page (NASDAQ:CLRB) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectar Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
